• SHOP
    • COMBOS
    • TESTIMONIALS
    • CART
    • INGREDIENTS
      • 2-DEOXY-D-GLUCOSE (2DG)
      • ACACIA CYANOPHYLLA FLOWER
      • ACORI GRAMINEI RHIZOMA
      • AEGLE MARMELOS CORREA
      • AGARICUS BLAZEI
      • AGED GARLIC EXTRACT
      • AFRAMOMUM MELEGUETA
      • ALOE ARBORESCENS
      • ALBIZIA
      • ALPINIA OFFICINARUM
      • ALTERNANTHERA SESSILIS
      • AMERICAN GINSENG
      • AMYGDALIN
      • ANACYCLUS PYRETHRUM
      • ANGELICA ARCHANGELICA
      • ANGELICA SINENSIS
      • ANTRODIA
      • APIGENIN
      • ARTICHOKE LEAF
      • ARTOCARPIN
      • AJUGA TURKESTANICA
      • ASHWAGANDHA
      • ASPALATHIN
      • ASTRAGALUS COMPLANATUS
      • AVENA SATIVA
      • BACOPA MONNIERI
      • BAVACHIN
      • BEE POLLEN
      • BETULINIC ACID
      • BOSWELLIC ACID
      • BREVILIN A
      • CAMPESTEROL
      • CAPSAICIN
      • CARCININE
      • CASTICIN
      • CHRYSIN
      • CIANIDANOL
      • CINNAMOMUM ZEYLANICUM
      • CITRULLUS COLOCYNTHIS
      • CITRUS RETICULATA PEEL
      • CODONOPSIS
      • CONJUGATED LINOLEIC ACID
      • COSTUNOLIDE
      • CYANIDIN
      • CUCURBITACIN D
      • DAIDZEIN
      • DECURSIN
      • DELPHINIDIN
      • DIGITALIS PURPREA (DIGOXIN)
      • DIOSMIN
      • ELLAGIC ACID
      • EMBELIN
      • ERIODICTYOL
      • GALLIC ACID
      • GLYCITEIN
      • GLYCYRRHIZIN
      • HYPERFORIN
      • ICARIIN
      • ISORHAMNETIN
      • ISOORIENTIN
      • ISOVITEXIN
      • JACEOSIDIN
      • KAEMPFEROL
      • KIGELIA AFRICANA
      • KURARINONE
      • LEMON BALM
      • LICORICIDIN
      • LIPOIC ACID
      • LUPEOL
      • MAGNOLOL
      • MENAQUINONE 4
      • MULBERRY LEAF
      • NARINGENIN
      • NOBILETIN
      • OLEACEIN
      • OLEANOLIC ACID
      • OLIVE OIL
      • ORIDONIN
      • PARTHENOLIDE
      • PHLOROGLUCINOL
      • PHLORIZIN
      • PICEATANNOL
      • PRISTIMERIN
      • PROANTHOCYANIDINS
      • PROCYANIDIN B3
      • PSEUDOLARIC ACID B
      • PTEROSTILBENE
      • RUTIN
      • SOLIDAGO VIRGAUREA
      • TANGERETIN
      • TARAXASTEROL
      • TRICHOSTATIN A
      • WEDELOLACTONE
      • WOGONIN
      • YERBA MATE
    • ABOUT
    • SCIENTIFIC STUDIES
      • ADAPTOGENS
      • ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
      • ADDICTION & THE BRAIN
      • ADDICTION & STRESS
      • ADDICTION WITHDRAWAL
      • ADIPOCYTE DEDIFFERENTIATION (THE REVERSAL OF FAT FORMATION)
      • ADIPOCYTE DIFFERENTIATION
      • ADROPIN
      • ALLERGIES & CYTOKINES
      • ALDOSTERONE & OBESITY/HYPERTENSION
      • ALZHEIMER’S, DEMENTIA, PARKINSON’S
      • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
      • ADVANCED GLYCATION END PRODUCTS (AGES)
      • ADDICTION TREATMENT
      • ADDICTION & DOPAMINE
      • AMPK
      • ANTI AGING
      • ANTIAGING EFFECTS OF COFFEE
      • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-APOPTOTIC PATHWAYS
      • ANTI ATHEROGENIC
      • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI CARIOGENIC (Protecting From Tooth Decay)
      • ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
      • ANTI GLYCATIVE
      • ANTI GLYCATION AGENTS
      • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI WRINKLE AGENTS
      • ANXIOLYTIC
      • APOPTOSIS
      • APOPTOSIS IN 3T3-L1
      • AUTOPHAGY
      • BCL-2
      • BCL-W
      • BCL-XL
      • BDNF
      • BECLIN-1 & AUTOPHAGY
      • BH3 MIMETICS
      • BIM aka BCL2L11
      • BIOMIMETIC HYDROXYAPATITE
      • BMI-1
      • BPA & OBESITY
      • BRASSINOSTEROIDS
      • CALORIE RESTRICTION
      • CALORIE RESTRICTION & LIFESPAN EXTENSION
      • CARBAMYLATION
      • CARBONYL SCAVENGER
      • CARBONYL STRESS
      • CARDIOPROTECTIVE AGENTS
      • CARDIAC GLYCOSIDES
      • CATALASE
      • CELL CYCLE ARREST
      • CENTENARIANS
      • CDK5
      • CHOLESTEROL EFFLUX
      • COGNITIVE ENHANCEMENT
      • COLD SHOCK PROTEINS
      • COLD-INDUCIBLE RNA-BINDING PROTEIN (CIRBP) & DNA REPAIR
      • CONDITIONED PLACE PREFERENCE
      • CORTICOTROPIN RELEASING FACTOR
      • CRYOTHERAPY
      • CRYOLIPOLYSIS: FREEZING FAT TO DEATH
      • CYP2E1
      • CYTOKINES IN PAIN, INFLAMMATION & AGING
      • DAF-16
      • DEPERSONALIZATION
      • DIABETES & CANCER
      • DIHYDROTESTOSTERONE (DHT)
      • DNA METHYLATION & AGING
      • DNA REPAIR
      • DNA REPAIR VIA FLAVONOIDS & POLYPHENOLS
      • DRY FASTING AND FLUID RESTRICTION FASTING
      • DYNORPHIN
      • ELLAGITANNINS
      • ENDOCRINE DISRUPTING CHEMICALS
      • ENLARGED HEART AND CARDIOMEGALY
      • EPIGENETIC MODIFIERS
      • EPINEPHRINE
      • ERGOGENIC AGENTS (INCREASE ATHLETIC PERFORMANCE)
      • EXCITOXICITY & THE BRAIN
      • EXTRACELLULAR MATRIX STIFFENING (10TH HALLMARK OF AGING)
      • EXTENDS LIFESPAN
      • EXTINCTION TRAINING
      • FASTING & THE BRAIN
      • FASTING & CANCER
      • FASTING MIMICKING DIET
      • FEAR EXTINCTION
      • FGF21
      • FLAVONES
      • GABA (γ-AMINOBUTYRIC ACID)
      • GALLOTANNINS
      • GLUCONEOGENESIS
      • GLUCOCORTICOID RECEPTOR ACTIVATION
      • GLUTAMATE & BRAIN
      • GLYCATION
      • GUT BRAIN AXIS
      • KLOTHO
      • K OPIOD RECEPTOR & ADDICTION
      • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
      • FOXO3
      • FOXO4
      • HALLMARKS OF AGING
      • HAIR REPIGMENTATION
      • HEPATOPROTECTIVE AGENTS (KEEPING LIVER HEALTHY)
      • HMGB1
      • HORMESIS
      • HPA AXIS
      • HSP70, THE ANTI-AGING PROTEIN
      • HSP90 INHIBITORS
      • HYPERGLYCEMIA
      • HYPERALGESIA
      • HYPERINSULINEMIA
      • HYPOTHALAMIC PITUITARY ADRENAL HPA AXIS
      • HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
      • HYPOCRETIN OREXIN
      • IKK
      • IL-6/STAT3
      • IRISIN
      • ISOFLAVONES
      • IMMUNOSENESCENCE
      • INCREASE PROTEIN SYNTHESIS
      • INFECTOBESITY
      • INFLAMMATION & ANXIETY
      • INFLAMMATION & CANCER
      • INFLAMMATION & DEPRESSION
      • INFLAMMATION & OBESITY
      • INFLAMMAGING
      • INHIBITION OF RENAL GLUCOSE REABSORPTION
      • INSULIN & AGING
      • INSULIN & CANCER: HOW INSULIN LITERALLY PROTECTS CANCER CELLS FROM BEING KILLED
      • INSULIN & MTOR
      • INSULIN & OBESITY
      • INSULIN OXIDATIVE STRESS
      • INTERMITTENT FASTING
      • JAK INHIBITION ALLEVIATES SASP
      • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
      • KETONE BODIES
      • KETOGENIC DIET
      • LEYDIG CELL STEROIDOGENESIS
      • LIFESPAN EXTENSION
      • LIPOLYTIC AGENTS
      • LIPID DROPLETS
      • LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
      • LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS
      • MATRIX METALLOPROTEINASES (MMPs)
      • MCL-1
      • MDM2 INHIBITION AS SASP INHIBITOR
      • MEDITERRANEAN DIET
      • METABOLIC REPROGRAMMING
      • METABOLIC SYNDROME
      • METHIONINE RESTRICTION
      • MITOCHONDRIAL UNCOUPLING
      • MONKEYPOX
      • MSG (MONOSOSODIUM GLUTAMATE)
      • MUSCLE FORCE PRODUCTION
      • MUSCLE ATROPHY (PREVENTING)
      • MYOGENESIS
      • MYOSTATIN INHIBITION
      • MYOSTATIN INHIBITION PRESERVES MUSCLE
      • mTORC2
      • mTOR: THE RAPID AGING PATHWAY
      • NATURAL ANTICOAGULANTS
      • NATURAL AROMATASE INHIBITORS
      • NEUROGENESIS (GROWING NEW BRAIN CELLS)
      • NEUROCHEMISTRY OF ADDICTION
      • NEUROPLASTICITY
      • NEUROINFLAMMATION
      • NEUROPROTECTIVE AGENTS
      • NEUTRALIZING OXIDATIVE STRESS WITH MEDICINAL PLANTS
      • NMDA & ANXIETY & DEPRESSION
      • NMDA RECEPTOR & FEAR
      • NON OPIOD ANALGESICS
      • NOOTROPICS
      • NORADRENERGIC
      • NOREPINEPHRINE
      • NRF2: MASTER REGULATOR OF THE AGING PROCESS
      • NF-KB
      • OBESOGENS
      • ONCOGENE ACTIVATION INDUCED SENESCENCE
      • OVERNUTRITION
      • OXIDATIVE STRESS & AGING
      • P16INK4A
      • P38MAPK
      • P53: TUMOR SUPRESSOR
      • PERIODONTITIS
      • PHYTOCHEMICALS
      • PHYTOSTEROLS
      • PHYTOSTANOLS
      • PHYTOECDYSTEROIDS
      • PROANTHOCYANIDINS
      • PROTEIN CARBONYLATION
      • POLYAMINES & THEIR EFFECT ON BRAIN (NMDA, DEPRESSION, SUICIDE RISK)
      • POLYPHENOLS AS COVID-19 TREATMENT & PREVENTION
      • PPARY2
      • PREMATURE SENESCENCE
      • PREVENTING SKIN AGING
      • PUFAS
      • PURGATIVES
      • RAPAMYCIN (MTOR INHIBITION)
      • RED WINE
      • RENAL (KIDNEY) PROTECTIVE AGENTS
      • REMINERALIZATION OF TEETH
      • REPAIR OF DNA BREAKS “DOUBLE STRAND”
      • RESTORE INSULIN SENSITIVITY
      • SASP & ADIPOSE TISSUE
      • SEX HORMONE BINDING GLOBULIN
      • SENESCENT CELLS, SASP & SENOLYTICS
      • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
      • SGLT2 INHIBITORS
      • SGLT2 INHIBITION FOR LIFESPAN EXTENSION
      • SHBG
      • SIRT1
      • SKELETAL MUSCLE HYPERTROPHY (THE SCIENCE OF BUILDING MUSCLE)
      • SKIN ELASTICITY
      • SKIN PHOTOAGING (Preventing & Repairing)
      • SLEEP DEPRIVATION AS THERAPY FOR DEPRESSION
      • SIRT1 & LONGEVITY
      • SMALLPOX
      • SUGAR & AGING
      • STAR PROTEIN
      • STAT3
      • STEM CELL EXHAUSTION
      • STEM CELL REGENERATION
      • STEM CELL THERAPY
      • STIMULATED LIPOLYSYS
      • STEROIDOGENESIS (THE PRODUCTION OF HORMONES IN BODY)
      • STREPTOCOCCUS MUTANS (MAIN BACTERIA BEHIND TOOTH DECAY)
      • STRESS & AGING
      • STRESS & THE BRAIN
      • TELOMERE SHORTENING & PREMATURE AGING
      • TIME RESTRICTED FEEDING
      • THROMBOLYTICS (PLANT BASED)
      • TRAUMATIC BRAIN INJURY (HEALING)
      • TRYPTOPHAN HYDROXYLASE 2
      • VISCERAL ADIPOSITY
      • XENOBIOTICS
      • XENOESTROGEN
    • HOME
    • CONTACT
    • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
    • The Ultimate Dry Fasting Resource
    0
    HPA AXIS
    December 22, 2021
    EXTRACELLULAR MATRIX STIFFENING (10TH HALLMARK OF AGING)
    January 21, 2022
    1. GLYCATION and diabetic complications
    2. Role of GLYCATION in aging
    3. Mechanisms of GLYCATION in atherogenesis
    4. The pathological implications of protein GLYCATION.
    5. GLYCATION products and the pathogenesis of diabetic complications
    6. Free radical generation by early GLYCATION products: a mechanism for accelerated atherogenesis in diabetes
    7. Advanced GLYCATION end-products and atherosclerosis
    8. Inhibition of protein GLYCATION and advanced GLYCATION end products by ascorbic acid and other vitamins and nutrients
    9. Advanced GLYCATION endproducts in ageing and Alzheimer’s disease
    10. GLYCATION and oxidation: a role in the pathogenesis of atherosclerosis
    11. Recent progress in advanced GLYCATION end products and diabetic complications
    12. Protein GLYCATION and oxidative stress in diabetes mellitus and ageing
    13. Tobacco smoke is a source of toxic reactive GLYCATION products
    14. Hydrogen peroxide production during experimental protein GLYCATION
    15. Diabetes, advanced GLYCATION endproducts and vascular disease
    16. Atherogenesis and Advanced GLYCATION: Promotion, Progression, and Preventiona
    17. Advanced GLYCATION end products in Alzheimer’s disease and other neurodegenerative diseases
    18. Recent progress in advanced GLYCATION and diabetic vascular disease: role of advanced GLYCATION end product receptors
    19. Lipoprotein GLYCATION and its metabolic consequences
    20. Advanced GLYCATION end products, oxidant stress and vascular lesions
    21. GLYCATION of collagen: the basis of its central role in the late complications of ageing and diabetes
    22. Formation of crossline as a fluorescent advanced GLYCATION end productin vitroandin vivo
    23. Advanced GLYCATION end products contribute to amyloidosis in Alzheimer disease
    24. GLYCATION of proteins as a source of superoxide.
    25. Advanced GLYCATION end products increase retinal vascular endothelial growth factor expression.
    26. Renal catabolism of advanced GLYCATION end products: the fate of pentosidine
    27. Survey of the distribution of a newly characterized receptor for advanced GLYCATION end products in tissues
    28. Plasma levels of pentosidine in diabetic patients: an advanced GLYCATION end product.
    29. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced GLYCATION endproducts
    30. Advanced GLYCATION endproducts and cigarette smoking.
    31. Cytotoxicity of advanced GLYCATION endproducts is mediated by oxidative stress
    32. GLYCATION induces expansion of the molecular packing of collagen
    33. In vitro kinetic studies of formation of antigenic advanced GLYCATION end products (AGEs): novel inhibition of post-Amadori GLYCATION pathways
    34. Lipoprotein GLYCATION and its metabolic consequences.
    35. Enhanced cellular oxidant stress by the interaction of advanced GLYCATION end products with their receptors/binding proteins
    36. Determination of advanced GLYCATION end products in serum by fluorescence spectroscopy and competitive ELISA
    37. Effect of phosphate on the kinetics and specificity of GLYCATION of protein.
    38. Pathways of formation of glycoxidation products during GLYCATION of collagen
    39. Breakers of advanced GLYCATION end products restore large artery properties in experimental diabetes
    40. Implication of an increased oxidative stress in the formation of advanced GLYCATION end products in patients with end-stage renal failure
    41. Non-enzymic GLYCATION of individual plasma proteins in normoglycemic and hyperglycemic patients.
    42. Role of fructose in GLYCATION and cross-linking of proteins
    43. The Advanced GLYCATION End Product, N∊-(Carboxymethyl) lysine, Is a Product of both Lipid Peroxidation and Glycoxidation Reactions (∗)
    44. Advanced GLYCATION end products up-regulate gene expression found in diabetic glomerular disease
    45. Vascular hypertrophy in experimental diabetes. Role of advanced GLYCATION end products.
    46. Orally absorbed reactive GLYCATION products (glycotoxins): an environmental risk factor in diabetic nephropathy
    47. The role of GLYCATION cross-links in diabetic vascular stiffening
    48. The relationship between accumulation of advanced GLYCATION end products and expression of vascular endothelial growth factor in human diabetic retinas
    49. GLYCATION-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells.
    50. Advanced GLYCATION end products in age-related macular degeneration
    51. Modification of low density lipoprotein by advanced GLYCATION end products contributes to the dyslipidemia of diabetes and renal insufficiency
    52. Increased serum levels of advanced GLYCATION end-products and diabetic complications
    53. RAGE: a novel cellular receptor for advanced GLYCATION end products
    54. Identification of the site of GLYCATION of human insulin
    55. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced GLYCATION end products.
    56. Advanced GLYCATION end products induce glomerular sclerosis and albuminuria in normal rats
    57. Cellular receptors for advanced GLYCATION end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions.
    58. Protein GLYCATION in the kidney: role in diabetes and aging
    59. Alzheimer’s disease–synergistic effects of glucose deficit, oxidative stress and advanced GLYCATION endproducts
    60. Expression of receptors for advanced GLYCATION end products in peripheral occlusive vascular disease
    61. GLYCATION and advanced GLYCATION end-product formation with icodextrin and dextrose
    62. Advanced GLYCATION end products in vitreous: Structural and functional implications for diabetic vitreopathy.
    63. Oxidative GLYCATION and free radical production: a causal mechanism of diabetic complications
    64. Oxidation conspires with GLYCATION to generate noxious advanced GLYCATION end products in renal failure.
    65. ELISA of pentosidine, an advanced GLYCATION end product, in biological specimens
    66. Failure of common GLYCATION assays to detect GLYCATION by fructose
    67. GLYCATION and inactivation of human Cu-Zn-superoxide dismutase. Identification of the in vitro glycated sites.
    68. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced GLYCATION end products
    69. Immunohistochemical detection of imidazolone, a novel advanced GLYCATION end product, in kidneys and aortas of diabetic patients.
    70. Evidence for the GLYCATION hypothesis of aging from the food-restricted rodent model
    71. Clearance of pentosidine, an advanced GLYCATION end product, by different modalities of renal replacement therapy
    72. Nonenzymatic GLYCATION of collagen in aging and diabetes
    73. Immunochemical approach to characterize advanced GLYCATION end products of the Maillard reaction: evidence for the presence of a common structure
    74. Advanced GLYCATION endproducts (AGEs) induce oxidant stress in the gingiva: a potential mechanism underlying accelerated periodontal disease associated with …
    75. GLYCATION alters collagen fibril organization
    76. Advanced GLYCATION endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits
    77. GLYCATION, glycoxidation, and cross-linking of collagen by glucose: kinetics, mechanisms, and inhibition of late stages of the Maillard reaction
    78. GLYCATION (non-enzymic glycosylation) inactivates glutathione reductase
    79. GLYCATION-induced inactivation and loss of antigenicity of catalase and superoxide dismutase
    80. Advanced GLYCATION endproducts stimulate interleukin‐6 production by human bone‐derived cells
    81. Advanced GLYCATION end product-induced activation of NF-κB is suppressed by α-lipoic acid in cultured endothelial cells
    82. Specific fluorescence assay for advanced GLYCATION end products in blood and urine of diabetic patients
    83. N. epsilon.-(Carboxymethyl) lysine is a dominant advanced GLYCATION end product (AGE) antigen in tissue proteins
    84. Advanced GLYCATION end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury
    85. Effect of curcumin on the advanced GLYCATION and cross-linking of collagen in diabetic rats
    86. Rapid formation of advanced GLYCATION end products by intermediate metabolites of glycolytic pathway and polyol pathway
    87. GLYCATION of amino groups in protein. Studies on the specificity of modification of RNase by glucose.
    88. Analysis of microtubule-associated protein tau GLYCATION in paired helical filaments.
    89. Role of protein-bound carbonyl groups in the formation of advanced GLYCATION endproducts
    90. Immunochemical evidence for the presence of advanced GLYCATION end products in human lens proteins and its positive correlation with aging.
    91. Role of advanced GLYCATION end-products (AGE) in late diabetic complications
    92. GLYCATION and Glycoxidation of Histones by ADP-ribose (∗)
    93. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental GLYCATION model of diabetes …
    94. The receptor for advanced GLYCATION end-products has a central role in mediating the effects of advanced GLYCATION end-products on the development of vascular …
    95. Advanced GLYCATION end products in neurodegeneration: more than early markers of oxidative stress?
    96. GLYCATION, oxidation, and lipoxidation in the development of diabetic complications
    97. GLYCATION of skin collagen in type I diabetes mellitus: correlation with long-term complications
    98. Nonenzymatic GLYCATION of type I collagen. The effects of aging on preferential GLYCATION sites.
    99. Site-specific and random fragmentation of Cu, Zn-superoxide dismutase by GLYCATION reaction. Implication of reactive oxygen species.
    100. Immunohistochemical and ultrastructural detection of advanced GLYCATION end products in atherosclerotic lesions of human aorta with a novel specific monoclonal …
    101. Long-term fructose consumption accelerates GLYCATION and several age-related variables in male rats
    102. Molecular identity and cellular distribution of advanced GLYCATION endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins
    103. Advanced GLYCATION end products induce crosslinking of collagen in vitro
    104. Decrease in skin collagen GLYCATION with improved glycemic control in patients with insulin-dependent diabetes mellitus.
    105. Increased levels of advanced GLYCATION endproducts in the lenses and blood vessels of cigarette smokers
    106. GLYCATION products in aged thioglycollate medium enhance the elicitation of peritoneal macrophages
    107. Localization in human diabetic peripheral nerve of Nɛ-carboxymethyllysine-protein adducts, an advanced GLYCATION endproduct
    108. A microassay for protein GLYCATION based on the periodate method
    109. Advanced GLYCATION end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats.
    110. Nonenzymatic GLYCATION of type IV collagen and matrix metalloproteinase susceptibility
    111. GLYCATION, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis
    112. Prevention of cardiovascular and renal pathology of aging by the advanced GLYCATION inhibitor aminoguanidine
    113. Increased pentosidine, an advanced GLYCATION end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory …
    114. Role of GLYCATION in modification of lens crystallins in diabetic and nondiabetic senile cataracts
    115. Advanced GLYCATION end-products in diabetic nephropathy
    116. Advanced GLYCATION end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS
    117. Specific GLYCATION of albumin depends on its half-life
    118. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced GLYCATION end-products: comparison with aminoguanidine
    119. The effects of ageing on GLYCATION and the interpretation of glycaemic control in Type 2 diabetes
    120. Nonenzymatic GLYCATION of collagen in aging and diabetes
    121. Chromatographic evidence for pyrraline formation during protein GLYCATION in vitro and in vivo
    122. Influence of advanced GLYCATION end-products and AGE-inhibitors on nucleation-dependent polymerization of β-amyloid peptide
    123. Standardizing the immunological measurement of advanced GLYCATION endproducts using normal human serum
    124. Significance of fructose-induced protein oxidation and formation of advanced GLYCATION end product
    125. Production and characterization of antibodies to advanced GLYCATION products on proteins
    126. Involvement of GLYCATION and oxidative stress in diabetic macroangiopathy
    127. Nonenzymatic GLYCATION: a central mechanism in diabetic microvasculopathy?
    128. Reducing sugars trigger oxidative modification and apoptosis in pancreatic β-cells by provoking oxidative stress through the GLYCATION reaction
    129. Hyperglycemia in hummingbirds and its consequences for hemoglobin GLYCATION
    130. Advanced GLYCATION End Product (AGE)–mediated induction of tissue factor in cultured endothelial cells Is dependent on RAGE
    131. GLYCATION of proteins by ADP-ribose
    132. Protein GLYCATION Inhibitors from Thyme (Thymus vulgaris)
    133. GLYCATION of monoclonal antibodies impairs their ability to bind antigen
    134. Receptor for advanced GLYCATION end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins
    135. Advanced GLYCATION end products induce expression of vascular endothelial growth factor by retinal Müller cells
    136. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced GLYCATION end products.
    137. Advanced GLYCATION end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus
    138. Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced GLYCATION end-product formation
    139. Advanced GLYCATION endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells
    140. The Receptor for Advanced GLYCATION End Products (RAGE) Is a Cellular Binding Site for Amphoterin: MEDIATION OF NEURITE OUTGROWTH AND CO …
    141. Factors in human serum interfere with the measurement of advanced GLYCATION endproducts.
    142. Changes in biomechanical properties, composition of collagen and elastin, and advanced GLYCATION endproducts of the rat aorta in relation to age
    143. Cross-linking and fluorescence changes of collagen by GLYCATION and oxidation
    144. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced GLYCATION end product: carbonyl stress in uremia.
    145. Effects of vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein GLYCATION in NIDDM
    146. Non-enzymatic GLYCATION of peripheral nerve proteins in human diabetics
    147. Effects of advanced GLYCATION end-products on the proliferation and differentiation of osteoblast-like cells
    148. Possible involvement of advanced GLYCATION end-products in bone resorption
    149. Immunohistochemical localization of different epitopes of advanced GLYCATION end products in human atherosclerotic lesions
    150. Activation of the receptor for advanced GLYCATION end products triggers a p21 ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress
    151. GLYCATION of rat sciatic nerve tubulin in experimental diabetes mellitus
    152. The serum concentration of the advanced GLYCATION end-product Nε-(carboxymethyl) lysine is increased in uremia
    153. Enhanced interaction of advanced GLYCATION end products with their cellular receptor RAGE: implications for the pathogenesis of accelerated periodontal disease in …
    154. Autoxidative glycosylation: free radicals and GLYCATION theory.
    155. Role of the Maillard reaction in aging of tissue proteins: advanced GLYCATION end product-dependent increase in imidazolium cross-links in human lens proteins
    156. Protein GLYCATION by ADP-ribose: studies of model conjugates
    157. Non-enzymic GLYCATION of human extracellular superoxide dismutase
    158. In vitro formation of advanced GLYCATION end products in peritoneal dialysis fluid
    159. Advanced GLYCATION endproducts—associated parameters in the peripheral blood of patients with Alzheimer’s disease
    160. Advanced GLYCATION end products in diabetic complications
    161. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced GLYCATION end products blocks hyperpermeability in diabetic …
    162. The relative UV sensitizer activity of purified advanced GLYCATION endproducts
    163. Nε-(Carboxymethyl)lysine Protein Adduct Is a Major Immunological Epitope in Proteins Modified with Advanced GLYCATION End Products of the Maillard Reaction
    164. Advanced GLYCATION endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human …
    165. Recombinant advanced GLYCATION end product receptor pharmacokinetics in normal and diabetic rats
    166. … characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced GLYCATION endproduct-modified serum …
    167. Decreased platelet membrane fluidity due to GLYCATION or acetylation of membrane proteins
    168. Identification of polymorphisms in the receptor for advanced GLYCATION end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups.
    169. Free radicals generated during the GLYCATION reaction of amino acids by methylglyoxal: a model study of protein-cross-linked free radicals
    170. The role of GLYCATION in aging and diabetes mellitus
    171. Advanced GLYCATION end products-driven angiogenesis in vitro: induction of the growth and tube formation of human microvascular endothelial cells through autocrine …
    172. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced GLYCATION endproduct formation and prevents hyperglycemia-induced …
    173. Immunohistochemical localisation of advanced GLYCATION end products in pulmonary fibrosis.
    174. Nonenzymatic GLYCATION of bovine serum albumin by fructose (fructation): comparison with the Maillard reaction initiated by glucose
    175. α-Lipoate can protect against GLYCATION of serum albumin, but not low-density lipoprotein
    176. Oxidative alterations in the experimental GLYCATION model of diabetes mellitus are due to protein-glucose adduct oxidation. Some fundamental differences in proposed …
    177. Accumulation of advanced GLYCATION end products of the Maillard reaction with age in human hippocampal neurons
    178. The relative roles of advanced GLYCATION, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley …
    179. Advanced GLYCATION end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the …
    180. GLYCATION of insulin results in reduced biological activity in mice
    181. The generation of superoxide anions in GLYCATION reactions with sugars, osones, and 3-deoxyosones
    182. Cytotoxic effects of autoxidative GLYCATION
    183. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced GLYCATION end products of the Maillard reaction
    184. Amyloid-β peptide–Receptor for Advanced GLYCATION Endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory …
    185. Sites of GLYCATION of human and horse liver alcohol dehydrogenase in vivo.
    186. Protein GLYCATION: measurement and clinical relevance
    187. Kinetic analysis of GLYCATION as a tool for assessing the half-life of proteins
    188. Advanced GLYCATION end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells
    189. Influence of GLYCATION on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells
    190. Characterization of in vitro GLYCATION sites of tau
    191. Non-enzymatic GLYCATION of apolipoprotein B in the sera of diabetic and non-diabetic subjects
    192. Histones from diabetic rats contain increased levels of advanced GLYCATION end products
    193. The contribution of GLYCATION to cataract formation in diabetes.
    194. Immunochemical detection of advanced GLYCATION end products in lens crystallins from streptozocin-induced diabetic rat
    195. Role of polyol pathway in nonenzymatic GLYCATION
    196. Increased Aggregation of Human Platelets Produced by Advanced GLYCATION End Productsin Vitro
    197. DNA-GLYCATION leads to depurination by the loss of N2-carboxyethylguanine in vitro.
    198. Immunohistochemical localization of advanced GLYCATION end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer’s disease and aged …
    199. Neurotoxicity of advanced GLYCATION endproducts during focal stroke and neuroprotective effects of aminoguanidine.
    200. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced GLYCATION–modified proteins to a conserved motif
    201. Nonenzymatic GLYCATION alters protein structure and stability. A study of two eye lens crystallins.
    202. Non-enzymic GLYCATION of fibrous collagen: reaction products of glucose and ribose
    203. Advanced GLYCATION end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with …
    204. DNA cleavage induced by GLYCATION of Cu, Zn-superoxide dismutase
    205. … in post-translational modification of collagen in normal human articular cartilage: the age-related increase in non-enzymatic GLYCATION affects biomechanical properties …
    206. Advanced GLYCATION endproducts stimulate the MAP-kinase pathway in tubulus cell line LLC-PK1
    207. Identification of pentosidine as a native structure for advanced GLYCATION end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related …
    208. GLYCATION, oxidative stress, and scavenger activity: glucose metabolism and radical scavenger dysfunction in endothelial cells
    209. Mutual interaction between GLYCATION and oxidation during non-enzymatic protein modification
    210. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced GLYCATION end products via a receptor-mediated mechanism
    211. Modification of vitronectin by advanced GLYCATION alters functional properties in vitro and in the diabetic retina.
    212. ADP-ribose in GLYCATION and glycoxidation reactions
    213. GLYCATION and microglial reaction in lesions of Alzheimer’s disease
    214. Progressive changes in lens crystallin GLYCATION and high-molecular-weight aggregate formation leading to cataract development in streptozotocin-diabetic rats
    215. The receptor for advanced GLYCATION end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via …
    216. Advanced GLYCATION endproducts and diabetic nephropathy
    217. Site specificity of protein GLYCATION
    218. The advanced GLYCATION endproduct pentosidine and monocyte activation in uremia.
    219. Advanced GLYCATION end products and their recognition by macrophage and macrophage-derived cells
    220. Toxic action of advanced GLYCATION end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy
    221. GLYCATION of crystalline in lenses from aging and diabetic individuals
    222. Increased serum levels of advanced GLYCATION end products (AGEs) in children and adolescents with IDDM
    223. Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced GLYCATION and diabetic complications
    224. Roles of advanced GLYCATION end-products in the progression of diabetic nephropathy
    225. The advanced GLYCATION end product Nepsilon-(carboxymethyl) lysine is increased in serum from children and adolescents with type 1 diabetes.
    226. Type II alveolar epithelial cells in lung express receptor for advanced GLYCATION end products (RAGE) gene
    227. Deposition of advanced GLYCATION end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat.
    228. Relative contributions of advanced GLYCATION and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats
    229. GLYCATION of insulin in the islets of Langerhans of normal and diabetic animals
    230. Advanced nonenzymatic GLYCATION endproducts (AGE): their relevance to aging and the pathogenesis of late diabetic complications.
    231. GLYCATION changes the charge distribution of type I collagen fibrils
    232. Age-related increase in an advanced GLYCATION end product in penile tissue
    233. Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced GLYCATION end products
    234. GLYCATION of brain actin in experimental diabetes
    235. Enhanced binding of advanced GLYCATION endproducts (AGE) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer’s disease
    236. Advanced GLYCATION endproducts are associated with Hirano bodies in Alzheimer’s disease
    237. GLYCATION accelerates the oxidation of low density lipoprotein by copper ions
    238. Relationships between GLYCATION and oxidation related fluorescences in rat collagen during aging. An in vivo and in vitro study.
    239. β2-Microglobulin modified with advanced GLYCATION end products modulates collagen synthesis by human fibroblasts
    240. Nonenzymatic GLYCATION of peripheral and central nervous system proteins in experimental diabetes mellitus
    241. A preliminary note on inhibiting effect of alpha-tocopherol (vit. E) on protein GLYCATION.
    242. Acid-stable fluorescent advanced GLYCATION end products: vesperlysines A, B, and C are formed as crosslinked products in the Maillard reaction between lysine or …
    243. … of methylglyoxal-modified serum albumin. Competition with advanced GLYCATION end product-modified serum albumin at the advanced GLYCATION end product receptor.
    244. GLYCATION increases the permeability of proteins across the blood-nerve and blood-brain barriers
    245. Immunochemical detection of advanced GLYCATION end products in renal cortex from STZ-induced diabetic rat
    246. Advanced GLYCATION end products co-localized with astrocytes and microglial cells in Alzheimer’s disease brain
    247. Site specificity of GLYCATION of horse liver alcohol dehydrogenase in vitro
    248. The influence of advanced GLYCATION endproducts (AGE) on the expression of human endothelial adhesion molecules
    249. Prevention of lens protein GLYCATION by taurine
    250. Inhibition of GLYCATION of albumin and hemoglobin by acetylation in vitro and in vivo
    251. Kinetics of nonenzymatic GLYCATION of ribonuclease A leading to advanced GLYCATION end products. Paradoxical inhibition by ribose leads to facile isolation of protein …
    252. Cellular contraction of collagen lattices is inhibited by nonenzymatic GLYCATION
    253. Nonenzymatic GLYCATION of human lens crystallin. Effect of aging and diabetes mellitus.
    254. Comparison of advanced GLYCATION endproducts on haemoglobin (Hb-AGE) and haemoglobin A1c for the assessment of diabetic control
    255. Lens protein composition, GLYCATION and high molecular weight aggregation in aging rats.
    256. Effects of metformin on collagen GLYCATION and diastolic dysfunction in diabetic myocardium
    257. The endothelial cell binding site for advanced GLYCATION end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide
    258. Thiamine corrects delayed replication and decreases production of lactate and advanced GLYCATION end-products in bovine retinal and human umbilical vein …
    259. Are advanced GLYCATION end-products associated with amyloidosis in Alzheimer’s disease?
    260. Evidence for an increased GLYCATION of IgG in diabetic patients
    261. GLYCATION of very low density lipoprotein from rat plasma impairs its catabolism
    262. In vivo GLYCATION of aldehyde reductase, a major 3-deoxyglucosone reducing enzyme: identification of GLYCATION sites
    263. The receptor for advanced GLYCATION end products mediates the chemotaxis of rabbit smooth muscle cells
    264. Atherosclerosis and GLYCATION
    265. Inhibitory effect of metformin on formation of advanced GLYCATION end products
    266. Advanced GLYCATION of rat liver histone octamers: an in vitro study
    267. The role of metal-catalyzed oxidation in the formation of advanced GLYCATION end products: an in vitro study on collagen
    268. Characterization of insulin GLYCATION in insulin-secreting cells maintained in tissue culture
    269. Glutathione inhibits the GLYCATION and crosslinking of lens proteins by ascorbic acid
    270. GLYCATION of human serum albumin: inhibition by Diclofenac
    271. GLYCATION of lens proteins by the oxidation products of ascorbic acid
    272. Immunohistochemical detection of advanced GLYCATION end products in dialysis-related amyloidosis
    273. Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced GLYCATION endproducts in lesions, and extent of atherosclerosis in LDL receptor …
    274. Effect of alpha-tocopherol on LDL oxidation and GLYCATION: in vitro and in vivo studies
    275. Advanced GLYCATION endproducts in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis
    276. Decrease in GLYCATION of lens proteins by lysine and glycine by scavenging of glucose and possible mitigation of cataractogenesis
    277. The site of nonenzymic GLYCATION of human extracellular-superoxide dismutase in vitro
    278. Immunohistochemical distribution and subcellular localization of three distinct specific molecular structures of advanced GLYCATION end products in human tissues.
    279. Structural and functional changes of laminin and type IV collagen after nonenzymatic GLYCATION
    280. Advanced GLYCATION end products (AGE)-modified proteins and their potential relevance to atherosclerosis
    281. Plasma protein GLYCATION as measured by fructosamine assay.
    282. Immunohistochemical study of advanced GLYCATION end products in aging and Alzheimer’s disease brain
    283. Pathophysiology of advanced GLYCATION end-products in renal failure
    284. Advanced GLYCATION endproducts–receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B
    285. Inhibition of lens crystallin GLYCATION and high molecular weight aggregate formation by aspirin in vitro and in vivo.
    286. Oxidative stress caused by GLYCATION of Cu, Zn-superoxide dismutase and its effects on intracellular components
    287. Advanced GLYCATION end product (AGE): Characterization of the products from the reaction between D‐glucose and serum albumin
    288. Hb himeji or β140 (H18) ALA→ ASP a slightly unstable hemoglobin with increased βN-terminal GLYCATION
    289. Age-dependent accumulation of advanced GLYCATION end-products in adult Drosophila melanogaster
    290. Characterization of the non enzymatic GLYCATION of high density lipoprotein in diabetic patients.
    291. The advanced GLYCATION endproduct pentosidine induces the expression of PDGF-B in human retinal pigment epithelial cells
    292. Interaction between β2-microglobulin and advanced GLYCATION end products in the development of dialysis related-amyloidosis
    293. Fragmentation of ceruloplasmin following non-enzymatic GLYCATION reaction
    294. CARNOSINE PROTECTS PROTEINS AGAINST IN VITRO GLYCATION AND CROSS–LINKING
    295. Non-enzymic glycosylation (GLYCATION) of lens proteins by galactose and protection by aspirin and reduced glutathione
    296. Role of advanced GLYCATION end products in aging collagen
    297. The role of oxidative stress in the long‐term GLYCATION of LDL
    298. Imidazolone, a novel advanced GLYCATION end product, is present at high levels in kidneys of rats with streptozotocin-induced diabetes
    299. Plasma protein GLYCATION in Alzheimer’s disease
    300. Influence of age and long-term dietary restriction on enzymatically mediated crosslinks and nonenzymatic GLYCATION of collagen in mice
    301. Localization of advanced GLYCATION endproducts in the kidney of experimental diabetic rats
    302. Nonenzymatic GLYCATION of immunoglobulins leads to an impairment of immunoreactivity
    303. Depletion of reactive advanced GLYCATION endproducts from diabetic uremic sera using a lysozyme-linked matrix.
    304. GLYCATION of cataractous lens in non-diabetic senile subjects and in diabetic patients.
    305. Non enzymatic GLYCATION of apolipoprotein AI. Effects on its self-association and lipid binding properties
    306. Two-dimensional stress-relaxation behavior of human skin as influenced by non-enzymatic GLYCATION and the inhibitory agent aminoguanidine
    307. The relationship of glycaemic level to advanced GLYCATION end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster
    308. Isolation and characterization of advanced GLYCATION end products derived from the in vitro reaction of ribose and collagen
    309. GLYCATION of albumin: reaction with glucose, fructose, galactose, ribose or glyceraldehyde measured using four methods
    310. A fluorescamine-based assay for the degree of GLYCATION in bovine serum albumin
    311. Effect of GLYCATION on the properties of lipoprotein (a)
    312. Aminoguanidine and its pro-oxidant effects on an experimental model of protein GLYCATION
    313. … -alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein GLYCATION in patients with …
    314. Generation of active oxygen species from advanced GLYCATION end-products (AGE) under ultraviolet light A (UVA) irradiation
    315. The relative extent of GLYCATION of haemoglobin and albumin
    316. Monocyte/macrophage response to β2-microglobulin modified with advanced GLYCATION end products
    317. Aminoguanidine inhibits advanced GLYCATION end products formation on beta2-microglobulin.
    318. Evaluation of the fructosamine test for the measurement of plasma protein GLYCATION
    319. D-lysine effectively decreases the non-enzymic GLYCATION of proteins in vitro.
    320. Inhibition of matrix-induced bone differentiation by advanced GLYCATION end-products in rats
    321. Effect of Matrix GLYCATION on Expression of Type IV Collagen, MMP-2, MMP-9 and TIMP-1 by Human
    322. DNA damage by the GLYCATION products of glyceraldehyde 3-phosphate and lysine
    323. GLYCATION mediated lens crystallin aggregation and cross-linking by various sugars and sugar phosphates in vitro
    324. Accelerated formation of Nϵ-(carboxymethyl) lysine, an advanced GLYCATION end product, by glyoxal and 3-deoxyglucosone in cultured rat sensory neurons
    325. Localization of identified advanced GLYCATION end‐product structures, Nε=(carboxymethyl) lysine and pentosidine, in age‐related inclusions in human brains
    326. Effect of advanced GLYCATION end product–modified albumin on tissue factor expression by monocytes: role of oxidant stress and protein tyrosine kinase activation
    327. Membrane fluidity is related to the extent of GLYCATION of proteins, but not to alterations in the cholesterol to phospholipid molar ratio in isolated platelet membranes …
    328. Advanced GLYCATION endproducts stimulate mitogen-activated protein kinase and proliferation in rabbit vascular smooth muscle cells
    329. Role of GLYCATION in human lens protein structure change
    330. The effectiveness of putative anti-cataract agents in the prevention of protein GLYCATION.
    331. Good glycaemic control reduces oxidation and GLYCATION end-products in collagen of diabetic rats
    332. Human erythrocyte bisphosphoglycerate mutase: inactivation by GLYCATION in vivo and in vitro
    333. Association between the GLYCATION of erythrocyte membrane proteins and membrane fluidity
    334. Impairment by GLYCATION of immunoglobulin G Fc fragment function
    335. Induction of macrophage growth by advanced GLYCATION end products of the Maillard reaction.
    336. Decreased interaction of fibronectin, type iv collagen, and heparin due to nonenzymic GLYCATION. Implications for diabetes mellitus
    337. GLYCATION: a pathological modification in neuropathies?: a hypothesis.
    338. The effects of aminoguanidine on the GLYCATION (non-enzymic glycosylation) of lens proteins
    339. Nonenzymatic GLYCATION of transferrin: decrease of iron-binding capacity and increase of oxygen radical production
    340. Modification of β2m with advanced GLYCATION end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum
    341. Non‐enzymatic GLYCATION of histones
    342. Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of advanced GLYCATION end products
    343. beta 2-Microglobulin modified with advanced GLYCATION end products is a major component of hemodialysis-associated amyloidosis.
    344. Nonenzymatic GLYCATION and extractability of collagen in human atherosclerotic plaques
    345. Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to GLYCATION
    346. The erythrocyte calcium pump is inhibited by non-enzymic GLYCATION: studies in situ and with the purified enzyme
    347. Tetracyclines inhibit protein GLYCATION in experimental diabetes
    348. Identification of the site of non-enzymatic GLYCATION of glutathione peroxidase: rationalization of the GLYCATION-related catalytic alterations on the basis of three …
    349. Identification of galectin-3 as a high-affinity binding protein for advanced GLYCATION end products (AGE): a new member of the AGE-receptor complex
    350. GLYCATION of human lens proteins from diabetic and (nondiabetic) senile cataract patients
    351. GLYCATION and inactivation of sorbitol dehydrogenase in normal and diabetic rats
    352. Circulating advanced GLYCATION peptides in streptozotocin-induced diabetic rats: evidence for preferential modification of IgG light chains
    353. Changes in solubility, non-enzymatic GLYCATION, and fluorescence of collagen in tail tendons from diabetic rats
    354. Advanced GLYCATION end products modulate transcriptional regulation in mesangial cells
    355. Increased serum levels of advanced GLYCATION end products in NIDDM patients with diabetic complications
    356. Presence of dopa and amino acid hydroperoxides in proteins modified with advanced GLYCATION end products (AGEs): amino acid oxidation products as a possible …
    357. Reaction of advanced GLYCATION endproducts with renal tissue from normal and streptozotocin-induced diabetic rats: an ultrastructural study using colloidal gold …
    358. Nonenzymatic GLYCATION of fibronectin and alterations in the molecular association of cell matrix and basement membrane components in diabetes mellitus
    359. … of methylglyoxal, glyoxalase I inhibitor diesters and SD-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced GLYCATION …
    360. Possible significance of advanced GLYCATION end products in serum in end-stage renal disease and in late complications of diabetes
    361. Molecular chaperones protect against GLYCATION‐induced inactivation of glucose‐6‐phosphate dehydrogenase
    362. Association of elastin GLYCATION and calcium deposit in diabetic rat aorta
    363. Nonenzymatic GLYCATION of mesangial matrix and prolonged exposure of mesangial matrix to elevated glucose reduces collagen synthesis and proteoglycan charge
    364. Implication of altered redox regulation by antioxidant enzymes in the increased plasma pentosidine, an advanced GLYCATION end product, in uremia
    365. Accumulation of advanced GLYCATION endproducts in the rat nephron: link with circulating AGEs during aging
    366. Immunohistochemical study of human advanced GLYCATION end-products (AGE) and growth factors in cardiac tissues of patients on maintenance dialysis and with …
    367. Advanced GLYCATION end-products in the peritoneal fluid and in the peritoneal membrane of continuous ambulant peritoneal dialysis patients
    368. Distribution of advanced GLYCATION end products in the cerebellar neurons of dogs
    369. Specific detections of the early process of the GLYCATION reaction by fructose and glucose in diabetic rat lens
    370. Growth modulation of retinal microvascular cells by early and advanced GLYCATION products
    371. Amyloidosis, advanced GLYCATION end products and Alzheimer disease
    372. Flavonoid treatment reduces GLYCATION and lipid peroxidation in experimental diabetic rats
    373. A study on in vitro GLYCATION processes by matrix-assisted laser desorption ionization mass spectrometry
    374. Effect of extracellular matrix GLYCATION on endothelial cell adhesion and spreading: involvement of vitronectin
    375. Spectroscopic study on the effects of nonenzymatic GLYCATION in human alpha-crystallin.
    376. GLYCATION ligand binding motif in lactoferrin
    377. … isomerization (Amadori rearrangement) potential at the individual nonenzymic GLYCATION sites of hemoglobin A: preferential inhibition of GLYCATION by nucleophiles at …
    378. New hypothesis on etiopathogenesis of Alzheimer syndrome. Advanced GLYCATION end products (AGEs)
    379. Ascorbic acid GLYCATION: the reactions of L-threose in lens tissue
    380. Evaluation of IgG GLYCATION levels by matrix‐assisted laser desorption/ionization mass spectrometry
    381. Identification of Deoxy-D-Fructosyl Phosphatidylethanolamine as a Non-enzymic GLYCATION Product of Phosphatidylethanolamine and its Occurrence in Human Blood …
    382. Tau GLYCATION is involved in aggregation of the protein but not in the formation of filaments.
    383. GLYCATION of albumin, not glomerular basement membrane, alters permeability in an in vitro model
    384. Immunochemical quantification of crossline as a fluorescent advanced GLYCATION endproduct in erythrocyte membrane proteins from diabetic patients with or without …
    385. Temporal association between lens protein GLYCATION and cataract development in diabetic rats
    386. Fluorescence and immunochemical studies of advanced GLYCATION-related lens pigments.
    387. β2-Microglobulin modified with advanced GLYCATION end products induces interleukin-6 from human macrophages: Role in the pathogenesis of hemodialysis …
    388. Differential GLYCATION of rat α-, β-and γ-crystallins
    389. Receptors for advanced GLYCATION end-products (AGE)—expression by endothelial cells in non-diabetic uraemic patients
    390. Monitoring the progress of non‐enzymatic GLYCATION in vitro
    391. GLYCATION of human lens proteins: preferential GLYCATION of αA subunits
    392. Free alanine, aspartic acid, or glutamic acid reduce the GLYCATION of human lens proteins
    393. In vitro non-enzymatic GLYCATION and formation of browning products in the bovine lens α-crystallin
    394. Nonenzymatic GLYCATION of human platelet membrane proteins in vitro and in vivo.
    395. Amyloid β2-microglobulin is modified with imidazolone, a novel advanced GLYCATION end product, in dialysis-related amyloidosis
    396. Role of Albumin GLYCATION on the Erythrocyte Aggregation: An In Vitro Study
    397. Site-specific GLYCATION of lens crystallins by ascorbic acid
    398. Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced GLYCATION end products
    399. Protein GLYCATION and fluorescent material in human atheroma
    400. Reduction of plasma apolipoprotein-B by effective removal of circulating GLYCATION derivatives in uremia
    401. Identification of advanced GLYCATION end products of the Maillard reaction in Pick’s disease
    402. D-Lysine reduces the non-enzymatic GLYCATION of proteins in experimental diabetes mellitus in rats
    403. GLYCATION of calmodulin: chemistry and structural and functional consequences
    404. Protein GLYCATION in the aging male Sprague-Dawley rat: effects of antiaging diet restrictions
    405. Involvement of beta 2-microglobulin modified with advanced GLYCATION end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human …
    406. Nonenzymatic glycosylation (GLYCATION) of lens crystallins in diabetes and aging.
    407. Nonenzymatic GLYCATION of type I collagen modifies interaction with UMR 201-10B preosteoblastic cells
    408. GLYCATION of Human. beta. 2-Microglobulin in Patients with Hemodialysis-Associated Amyloidosis: Identification of the Glycated Sites
    409. Immunochemical evidence for increased formation of advanced GLYCATION end products and inhibition by aminoguanidine in diabetic rat lenses
    410. Amadori rearrangement potential of hemoglobin at its GLYCATION sites is dependent on the three-dimensional structure of protein
    411. The effect of δ-gluconolactone, an oxidised analogue of glucose, on the nonenzymatic GLYCATION of human and rat haemoglobin
    412. 3-Deoxyglucosone, a promoter of advanced GLYCATION end products in fluids for peritoneal dialysis
    413. A highly specific method for the characterization of GLYCATION and glyco‐oxidation products of globins
    414. The In Vitro GLYCATION of Lysozyme and the Influence of Buffer Concentration Investigated by Mass Spectrometry
    415. Biochemical alterations in collagen IV induced by in vitro GLYCATION
    416. GLYCATION and autoxidation of proteins in aging and diabetes
    417. Role of reactive oxygen species in the generation of fluorescence by GLYCATION
    418. GLYCATION of lipoproteins and accelerated atherosclerosis in non-insulin-dependent diabetes mellitus
    419. Potential benefit of inhibitors of advanced GLYCATION end products in the progression of type II diabetes: a study with aminoguanidine in C57/BLKsJ diabetic mice
    420. Inhibition of advanced protein GLYCATION by 8-quinolinecarboxylic hydrazide
    421. GLYCATION increases the vascular clearance rate of IgG in mice
    422. GLYCATION-induced inactivation of malate dehydrogenase protection by aspirin and a lens molecular chaperone, α-crystallin
    423. On glucose transport and non-enzymic GLYCATION of proteins in vivo
    424. Effect of nonenzymatic GLYCATION on the structure of immunoglobulin G
    425. Effects of matrix GLYCATION on mesangial cell adhesion, spreading and proliferation
    426. GLYCATION of lens membrane intrinsic proteins
    427. Differential expression of receptors for advanced GLYCATION end products on monocytes in patients with IDDM
    428. Nonenzymatic GLYCATION of cartilage proteoglycans: an in vivo and in vitro study
    429. The role of oxidation and GLYCATION in the pathogenesis of diabetic atherosclerosis
    430. Fructose-related GLYCATION
    431. Advanced GLYCATION end products of the Maillard reaction in aortic pepsin-insoluble and pepsin-soluble collagen from diabetic rats
    432. Sites of GLYCATION of βB2-crystallin by glucose and fructose
    433. Advanced GLYCATION end products of the Maillard reaction and their relation to aging
    434. Acceleration of fructose mediated collagen GLYCATION
    435. Advanced GLYCATION modification of Rosenthal fibers in patients with Alexander disease
    436. In vitro GLYCATION of glomerular basement membrane alters its permeability: a possible mechanism in diabetic complications
    437. Effect of GLYCATION of albumin on its renal clearance in normal and diabetic rats
    438. Alterations of biochemical and biomechanical properties of rat tail tendons caused by non-enzymatic GLYCATION and their inhibition by dibasic amino acids arginine and …
    439. Expression of receptors for advanced GLYCATION end-products in occlusive vascular and renal disease
    440. Plasma lipoproteins from patients with poorly controlled diabetes mellitus and “in vitro” GLYCATION of lipoproteins enhance the transfer rate of cholesteryl ester from HDL …
    441. Glyburide protein binding and the effect of albumin GLYCATION in children, young adults, and older adults with diabetes
    442. Formation of advanced GLYCATION end (AGE) products in diabetes: Prevention by pyruvate and a-keto glutarate
    443. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced GLYCATION endproducts in bovine endothelial cells.
    444. Nonenzymatic GLYCATION* of Basement Membranes From Human Glomeruli and Bovine Sources: Effect of Diabetes and Age
    445. GLYCATION of proteinous inhibitors: Loss in trypsin inhibitory activity by the blocking of arginine and lysine residues at their reactive sites
    446. Advanced GLYCATION endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with Rheumatoid Arthritis (RA).
    447. Evidence for a relationship between protein GLYCATION and red blood cell membrane fluidity
    448. Advanced GLYCATION end products in peritoneal dialysis
    449. Ribozyme targeting of receptor for advanced GLYCATION end products in mouse mesangial cells
    450. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced GLYCATION
    451. A study of the age-related acceleration of GLYCATION of tissue proteins in rats
    452. Some physico‐chemical properties and structural changes of bovine β‐casein upon GLYCATION
    453. GLYCATION index of hair for non-invasive estimation of diabetic control
    454. Streptozotocin-induced diabetes mellitus in cynomolgus monkeys: changes in carbohydrate metabolism, skin GLYCATION, and pancreatic islets
    455. Non-enzymatic GLYCATION reduces heparin cofactor II anti-thrombin activity
    456. Non-enzymatic GLYCATION of lipoprotein (a) in vitro and in vivo
    457. Post-translational non-enzymatic modification of proteins II. Separation of selected protein species after GLYCATION and other carbonyl-mediated modifications
    458. Inhibitory effect of nonenzymatic GLYCATION on ubiquitination and ubiquitin-mediated degradation of lysozyme
    459. Ascorbic acid GLYCATION of lens proteins produces UVA sensitizers similar to those in human lens
    460. Nonenzymatic GLYCATION of Na, K-ATPase. Effects on ATP hydrolysis and K+ occlusion.
    461. GLYCATION of myofibrillar protein in aged rats and mice
    462. Ageing promotes the increase of early GLYCATION Amadori product as assessed by ϵ-N-(2-furoylmethyl)-l-lysine (furosine) levels in rodent skin collagen: The …
    463. GLYCATION and inactivation of aspartate aminotransferase in diabetic rat tissues
    464. Amino terminal GLYCATION of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells
    465. GLYCATION of glucagon-like peptide-1 (7–36) amide: characterization and impaired action on rat insulin secreting cells
    466. The principal site of GLYCATION of human complement factor B
    467. Computer models of albumin and haemoglobin GLYCATION
    468. Interactions between the sorbitol pathway, non-enzymatic GLYCATION, and diabetic vascular dysfunction
    469. Angiogenic effects of advanced GLYCATION end products of the Maillard reaction on cultured human umbilical cord vein endothelial cells
    470. Nonenzymatic GLYCATION of human blood platelet proteins
    471. GLYCATION of albumin with aging and diabetes in rats: changes in its renal handling
    472. Increased GLYCATION of plasma lipoproteins in diabetic cynomolgus monkeys.
    473. Nonenzymic GLYCATION of human immunoglobulins does not impair their immunoreactivity.
    474. GLYCATION of the human erythrocyte glucose transporter in vitro and its functional consequences
    475. Age-and diabetes-accelerated GLYCATION in the human aorta
    476. Purification of α-ketoaldehyde dehydrogenase from the human liver and its possible significance in the control of GLYCATION
    477. Aging of the vitreous body. Role of GLYCATION and free radicals
    478. Non-enzymatic GLYCATION of epidermal proteins of the stratum corneum in diabetic patients
    479. Non-enzymatic GLYCATION and altered renal structure and function in the diabetic rat
    480. Primary Sequence and GLYCATION at Lysine‐548 of Bovine Serum Albumin
    481. Age-related acceleration of GLYCATION of tissue proteins in rats
    482. Change in the functional properties of actin by its GLYCATION in vitro.
    483. Site selectivity in the GLYCATION of αA-crystallin and αB-Crystallins by glucose
    484. Fructose-induced fluorescence generation of reductively methylated glycated bovine serum albumin: evidence for nonenzymatic GLYCATION of Amadori adducts
    485. Identification of GLYCATION at the N-terminus of albumin by gas chromatography-mass spectrometry
    486. Hyperglycemia and non-enzymatic GLYCATION of serum and tissue proteins in chickens
    487. The influence of GLYCATION on the peroxidase activity of haemoglobin
    488. GLYCATION of erythrocyte superoxide dismutase reduces its activity
    489. Determination of GLYCATION crosslinking by the sugar-dependent incorporation of [14C] lysine into protein
    490. Non-enzymatic GLYCATION of phosphoglucoisomerase.
    491. Impaired agglutination of IgM resulting from non-enzymatic GLYCATION in diabetes mellitus
    492. The GLYCATION hypothesis of atherosclerosis
    493. Improvement of physicochemical and enzymatic properties of bovine trypsin by non-enzymatic GLYCATION
    494. Non-enzymatic GLYCATION of elastin
    495. In vivo GLYCATION of bovine lens crystallins
    496. The pyridoindole antioxidant stobadine inhibited GLYCATION-induced absorbance and fluorescence changes in albumin
    497. … may condition antithrombin III biologic activity but not its plasma concentration in insulin-dependent diabetes. A possible role for labile non-enzymatic GLYCATION.
    498. Peripheral nerve protein GLYCATION and muscle fructolysis: evidence of abnormal carbohydrate metabolism in ALS.
    499. Nonenzymatic GLYCATION alters properties of collagen as a substratum for cells
    500. Free lysine, glycine, alanine, glutamic acid and aspartic acid reduce the GLYCATION of human lens proteins by galactose.
    501. In vitro studies of histone GLYCATION
    502. Post-translational non-enzymatic modification of proteins I. Chromatography of marker adducts with special emphasis to GLYCATION reactions
    503. Crystallin composition of human cataractous lens may be modulated by protein GLYCATION
    504. NA+/K+ ATPase Impairment and Experimental GLYCATION: The Role of Glucose Autoxidation
    505. Contribution of GLYCATION to human lens coloration
    506. ADVANCED GLYCATION TOXICITY AND DIABETIC COM PLI CATIONS
    507. Protein GLYCATION and in vivo distribution of human lens fluorescence
    508. GLYCATION of platelet protein in diabetes mellitus: lack of correlation with platelet function
    509. GLYCATION of serum albumin and its role in renal protein excretion and the development of diabetic nephropathy
    510. Polyclonal immunoglobulin M: location of GLYCATION sites
    511. Pathobiology of the heart in experimental diabetes: immunolocalization of lipoproteins, immunoglobulin G, and advanced GLYCATION endproducts proteins in diabetic …
    512. … of a serine protease in erythrocyte cytosol that is adherent to oxidized membranes and preferentially degrades proteins modified by oxidation and GLYCATION
    513. IgG GLYCATION and function during continuous ambulatory peritoneal dialysis.
    514. The Role of α-and ε-Amino Groups in the GLYCATION-mediated Cross-linking of γB-crystallin: STUDY OF THREE SITE-DIRECTED MUTANTS
    515. Characterization of the GLYCATION of albumin in freeze-dried and frozen human serum
    516. Effects of continuous ambulatory peritoneal dialysis and kidney transplantation on advanced GLYCATION endproducts in the skin and peritoneum.
    517. L-Arginine inhibits in vitro nonenzymatic GLYCATION and advanced glycosylated end product formation of human serum albumin
    518. Matrix‐assisted laser desorption/ionization mass spectrometric studies on protein GLYCATION. 2. The reaction of ribonuclease with hexoses
    519. The effect of fructose on collagen GLYCATION.
    520. GLYCATION of lens MIP26 affects the permeability in reconstituted liposomes
    521. The in vivo GLYCATION of diabetic tendon collagen studied by neutron diffraction
    522. Increased GLYCATION and pigmentation of collagen in aged and young parabiotic rats and mice
    523. GLYCATION-induced crosslinking of calf lens crystallins
    524. Some factors that influence the nonenzymatic GLYCATION of peptides and polypeptides by glyceraldehyde
    525. In vitro GLYCATION of red blood cell proteins: high levels of glucose lower lipid fluidity of erythrocyte membranes
    526. Relationship between lens protein GLYCATION and membrane structure in human cataract
    527. Comparison of the effect of different inhibitors on the non-enzymatic GLYCATION of rat tail tendons and bovine serum albumin
    528. GLYCATION and diabetic complications
    529. Nonenzymatic GLYCATION of platelet proteins in diabetic patients
    530. Identification of the site of GLYCATION of γ-II-crystallin by (14C)-fructose
    531. Nonenzymic GLYCATION of apolipoprotein B in patients with insulin-and noninsulin-dependent diabetes mellitus
    532. Non-enzymatic GLYCATION and protein recognition.
    533. The GLYCATION-associated crosslinking of lens proteins by ascorbic acid is not mediated by oxygen free radicals
    534. Inhibition of protein non-enzymic GLYCATION induced by Bendazac.
    535. Defects of copper deficiency in rats are modified by dietary treatments that affect GLYCATION
    536. Diminished adhesion of endothelial aortic cells on fibronectin and collagen layers after nonenzymatic GLYCATION
    537. Nonenzymic GLYCATION of albumin by acyl glucuronides in vitro comparison of reactions with reducing sugars
    538. Importance of advanced GLYCATION end products–AGE products
    539. Identification of furoyl-containing advanced GLYCATION products in collagen samples from diabetic and healthy rats
    540. GLYCATION of human lens crystallins: effect of age and aspirin treatment
    541. The nonenzymatic GLYCATION of proteins and nucleic acids, their importance for the development of diabetic complications, possible molecular basis of aging and …
    542. Non-enzymatic GLYCATION of antithrombin III in vitro
    543. Nonenzymatic GLYCATION of immunoglobulins does not impair antigen-antibody binding.
    544. Lysine vasopressin undergoes rapid GLYCATION in the presence of reducing sugars
    545. Kinetics of the GLYCATION of bovine serum albumin by mannose and fucose in vitro
    546. Non-enzymatic GLYCATION of human albumin does not alter its palmitate binding
    547. The GLYCATION and cross-linking of isolated lens crystallins by ascorbic acid
    548. Reduced membrane fluidity and increased GLYCATION of membrane proteins of platelets from diabetic subjects are not associated with increased platelet adherence to …
    549. Impaired immunoglobulin G Fc fragment function in diabetics is caused by a mechanism different from GLYCATION
    550. GLYCATION and oxidation of human low density lipoproteins reduces heparin binding and modifies charge
    551. In vitro GLYCATION and acetylation (by aspirin) of rat crystallins
    552. Matrix‐assisted laser desorption/ionization capabilities in the study of non‐enzymatic protein GLYCATION
    553. Effects of aminoguanidine on serum advanced GLYCATION endproducts, urinary albilmin excretion, mesangial expansion, and glomerular basement membrane …
    554. Bendazac decreases in vitro GLYCATION of human lens crystallins
    555. GLYCATION of human tissue and serum creatine kinase
    556. Nonenzymic GLYCATION of isolated human glomerular basement membrane changes its physicochemical characteristics and binding properties
    557. Inhibitory effects of some Chinese herbs on the non-enzymatic GLYCATION of proteins [J]
    558. GLYCATION decreases the stability of the triple-helical strands of fibrous collagen against proteolytic degradation by pepsin in a specific temperature range
    559. GLYCATION reaction of aspartate aminotransferase by various carbohydrates in an in vitro system
    560. Prevention and reversible solubilization of advanced GLYCATION and products (AGE) by organic germanium compounds as derivatives of amino acids
    561. GLYCATION of hemoglobin C in the heterozygous state in diabetic patients
    562. Improved metabolic control in patients with non‐insulin‐dependent diabetes mellitus is associated with a slower accumulation of GLYCATION products in collagen
    563. High galactose levels in vitro and in vivo impair ascorbate regeneration and increase ascorbate-mediated GLYCATION in cultured rat lens
    564. Determination of the non-enzymatic GLYCATION of hemoglobin by isoelectrofocusing of its globin chains
    565. Low GLYCATION level and browning in human cataracts
    566. Localization of advanced GLYCATION end products of Maillard reaction in bovine tissues and their endocytosis by macrophage scavenger receptors
    567. Advanced GLYCATION end products induce specific glycoprotein alterations in retinal microvascular cells
    568. Amyloid, advanced GLYCATION end products, and dialysis related arthropathy
    569. Role of Glycine 1 and Lysine 2 in the GLYCATION of Bovine γB-Crystallin: SITE-DIRECTED MUTAGENESIS OF LYSINE TO THREONINE (∗)
    570. Lens protein GLYCATION and the subsequent degree of opacity in streptozotocin-diabetic rats
    571. Protein GLYCATION: Effects upon protein recognition by the proximal tubule
    572. Variable GLYCATION of serum proteins in patients with diabetes mellitus
    573. Colorimetric assay of glycoprotein GLYCATION free of interference from glycosylation residues
    574. GLYCATION mediated crosslinking between α-crystallin and MP26 in intact lens membranes
    575. Advanced GLYCATION end-products reduce the viability of human peritoneal mesothelial cells
    576. The permselectivity of glomerular basement membrane can be compromised by GLYCATION or by exposure to low levels of hypochlorite
    577. Rapid assessment of early GLYCATION products by mass spectrometry
    578. Captopril inhibits the fluorescence development associated with GLYCATION of proteins.
    579. Advanced GLYCATION end products stimulate plasminogen activator activity via GM-CSF in RAW 264.7 cells
    580. Immunochemical detection of N2-[1-(1-carboxy) ethyl] guanosine, an advanced GLYCATION end product formed by the reaction of DNA and reducing sugars or L …
    581. Aging of aorta and atherosclerosis–role of nonenzymatic GLYCATION of collagen
    582. Plasma protein’s GLYCATION is decreased in Sprague Dawley rats under caloric restriction
    583. Retinol binding protein: a short half life determinant of protein non enzymatic GLYCATION in diabetes.
    584. Hepatic advanced GLYCATION endproduct binding is increased in experimental diabetes.
    585. Effects of GLYCATION process on the macromolecular structure of the glomerular basement membranes and on the glomerular functions in aging and diabetes mellitus
    586. Effect of creatine on GLYCATION of albumin in vitro
    587. Effect of alpha-glucosidase inhibition on the nonenzymatic GLYCATION of glomerular basement membrane.
    588. … by human monocytic THP-1 cells and chemotaxis induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced GLYCATION …
    589. … chromatofocusing and column affinity chromatography of in vitro14C-glycated human serum albumin: Demonstration of a GLYCATION-induced anionic heterogeneity
    590. Studies on advanced GLYCATION end products by recent mass spectrometric techniques
    591. Effect of GLYCATION on the heterogeneity of human serum albumin analysed by reversed-phase high-performance liquid chromatography in a solvent containing formic …
    592. Hair protein GLYCATION as a long-term index of blood glucose in diabetics
    593. Effects of advanced GLYCATION endproducts on the generation of macrophage-mediated oxidized low-density lipoprotein
    594. Susceptibility of Gamma‐Irradiated Proteins to In Vitro GLYCATION: Exposure to Oxygen Free Radicals Increases GLYCATION‐Induced Modifications
    595. Clinical application of hair protein GLYCATION in the assessment of blood glucose control and diabetic neuropathy.
    596. Comparison of normal and in vitro aging by non-enzymatic GLYCATION as verified by differential scanning calorimetry
    597. Effects of aminoguanidine and pyridoxal phosphate on GLYCATION reaction of aspartate aminotransferase and serum albumin
    598. Structural elucidation of a novel lysine-lysine crosslink generated in a GLYCATION reaction with L-threose
    599. … of synthesis and secretion of interleukin 1β in the human monocytic THP-1 cells by human serum albumins modified with methylglyoxal and advanced GLYCATION …
    600. Immunohistochemical study with anti‐advanced GLYCATION end‐products antibody in murine amyloidosis
    601. The lysine GLYCATION 1. A preliminary investigation on the products arising from the reaction of protected lysine and D-glucose
    602. GLYCATION of hepatocyte cytosolic proteins in streptozotocin-induced diabetic rats
    603. Advanced GLYCATION end products and β2-microglobulin. The story unfolds
    604. Quantitation of the GLYCATION intermediate 3-deoxyglucosone by oxidation with rabbit liver oxoaldehyde dehydrogenase to 2-keto-3-deoxygluconic acid followed by …
    605. Reduction of advanced GLYCATION end‐product (AGE) levels in nervous tissue proteins of diabetic Lewis rats following islet transplants is related to different durations of …
    606. Polypeptide-polysaccharide conjugates produced by spontaneous non-enzymatic GLYCATION
    607. GLYCATION of fibrinogen in diabetic patients: a practical colorimetric assay
    608. The role of GLYCATION in cataract lens in diabetic patients
    609. GLYCATION of granulocyte and monocyte membrane proteins in diabetic patients
    610. Reactivity of 6-phosphogluconolactone with hydroxylamine: the possible involvement of glucose-6-phosphate dehydrogenase in endogenous GLYCATION reactions
    611. Effect of protein GLYCATION on subsequent volatile formation
    612. Calmodulin GLYCATION in diabetic rat lenses
    613. Spectrophotometric determination of browning products of GLYCATION of protein amino groups based on their reactivity with nitro blue tetrazolium salts
    614. Lens glutathione, lens protein GLYCATION and electrophoretic patterns of lens proteins in STZ induced diabetic rats
    615. GLYCATION of collagen in hypertriglyceridemic rats
    616. Evidence for GLYCATION of horse liver alcohol dehydrogenase in vivo
    617. Automated fructosamine assay with improved accuracy used to quantify nonenzymatic GLYCATION of serum proteins in diabetes mellitus and chronic renal failure
    618. Serum levels of 3-deoxyglucosone and tissue contents of advanced GLYCATION end products are increased in streptozotocin-induced diabetic rats with nephropathy
    619. Application of the Time-Resolved Immunofluorometric Assay to the Study of C3 Complement Component GLYCATION in vitro and in vivo
    620. … and HDL-cholesterol independent of fasting triglycerides in a Caucasian population: evidence for enhanced cholesterol ester transfer induced by in vivo GLYCATION
    621. The adverse effect of GLYCATION of human serum albumin on its preservative activity in the freeze-drying and accelerated degradation of alkaline phosphatase
    622. … staining of renal biopsy samples in patients with diabetic nephropathy in non‐insulin dependent diabetes mellitus using monoclonal antibody to advanced GLYCATION …
    623. The effect of non-enzymic GLYCATION on ligand binding to human serum albumin
    624. Parent ion spectroscopy in the identification of advanced GLYCATION products
    625. Protein GLYCATION: Its role in the changes induced by diabetes in the properties of the serum insulin-like growth factor-I binding proteins
    626. The effect of non-enzymatic GLYCATION of serum proteins on their permeation into peripheral nerve in normal and streptozotocin-diabetic rats
    627. Molecular characterization of a mouse genomic element mobilized by advanced GLYCATION endproduct modified-DNA (AGE-DNA)
    628. Crossline-like structure accumulates as fluorescent advanced GLYCATION end products in renal tissues of rats with diabetic nephropathy
    629. Nonenzymatic GLYCATION of fibronectin impairs adhesive and proliferative properties of human vascular smooth muscle cells
    630. Influence of GLYCATION on cis/trans isomerization and tautomerization in novel morphiceptin-related Amadori compounds
    631. Protection by acetylsalicylic acid against hyperglycemia-induced GLYCATION and neural tube defects in cultured early somite mouse embryos.
    632. Effect of GLYCATION upon activity of liver alcohol dehydrogenase
    633. New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced GLYCATION end products in renal failure
    634. … monocytes and human monocytic THP-1 cells induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced GLYCATION …
    635. GLYCATION of H1-histone
    636. Relationship between vascular endothelial growth factors and advanced GLYCATION end products in the human vitreous
    637. Kinetics of histone protein GLYCATION.
    638. GLYCATION of MP26 and MP22 in bovine lens membranes
    639. An Electrospray Investigation on in vitro GLYCATION of Ribonuclease
    640. Effect of GLYCATION of low-density lipoprotein on the immunological determination of apolipoprotein B.
    641. Non-enzymic GLYCATION of proteins: analysis of N-(1-deoxyhexitol-1-yl) amino acids by high-performance liquid chromatography
    642. GLYCATION in neuropathies
    643. GLYCATION of myofibrillar proteins and ATPase activity after incubation with eleven sugars
    644. Effect of GLYCATION of albumin on its binding to renal brush-border membrane vesicles: influence of aging in rats
    645. Decreased actin activated myosin ATPase activity by non-enzymatic GLYCATION
    646. Phosphate promotes GLYCATION of antithrombin III which interferes with heparin binding
    647. Scheimpflug densitometric analysis of cataracts in diabetic rats: correlation with GLYCATION
    648. 132 Total antioxidant status, protein GLYCATION, lipid hydroperoxides in non insulin dependent diabetes mellitus
    649. Immunochemical determination of advanced GLYCATION end products in erythrocyte peripheral-membrane proteins from diabetic patients
    650. … -6-(2-formyl-5-hydroxymethyl-pyrrol-l-yl)-hexanoic acid (‘pyrraline’) as an early-stage product or advanced GLYCATION end product in non-enzymic protein GLYCATION
    651. Specific non-enzymatic GLYCATION of the rat histone H1 nucleotide binding site in vitro in the presence of AlF4−. A putative mechanism for impaired chromatin function
    652. Mass spectrometry in the study of advanced GLYCATION processes, responsible for long‐term diabetes complications
    653. The role of bound lipid and transition metal in the formation of fluorescent advanced GLYCATION endproducts by human serum albumin
    654. GLYCATION of tau protein
    655. Evidence that dimethyl sulfoxide inhibits defects of copper deficiency by inhibition of GLYCATION
    656. Formation of early and advanced GLYCATION products of lens crystallins with erythrose, ribose and glucose
    657. Enhanced nonenzymatic GLYCATION of eye lens proteins in experimental diabetes mellitus: an approach for the study of protein alterations as mediators of normal aging …
    658. Accelerated GLYCATION of the aorta in diabetic rats
    659. Nonenzymatic advanced GLYCATION in the lens membranes
    660. Influence of blood proteins on biomedical analysis. XII. Effects of GLYCATION on gliclazide (oral hypoglycemic drug)-binding with serum albumin in diabetics
    661. GLYCATION and Oxidation of Proteins: A Role in the Pathogenesis of Atherosclerosis?
    662. The GLYCATION of bovine lens βL-, βS-and γ-crystallins demonstrated by isoelectric focusing and lectin staining
    663. Kinetic behaviour of liver glucokinase in diabetes. II. Possible role of non-enzymatic protein GLYCATION.
    664. Experimental effect of puerarin on the formation of advanced GLYCATION end products and expression of RAGE in the arota of diabetic rats
    665. Diagnosis of the diabetic metabolic status using fructosamine (and HbA1c) determination. The GLYCATION quotient Glyc-Q, the GLYCATION nomogram
    666. Inactivation of glucose-6-phosphate dehydrogenase by GLYCATION
    667. GLYCATION of proteins and methods of its assessment
    668. Non‐Enzymatic GLYCATION of Fetal Tissue in Diabetic Pregnancy: Estimation of the Glucitollysine Content of Umbilical Cord Extracts
    669. Formation and ways of detecting advanced GLYCATION end-products in isolated human glomerular basement membrane and human serum albumin nonenzymatically …
    670. Effect of germanium-132 on galactose cataracts and GLYCATION in rats
    671. Studies on L-threose as substrate for aldose reductase: A possible role in preventing protein GLYCATION
    672. The Use of Solid Phase Extraction Cartridges as a Pre-Fractionation Step in the Quantisation of Intermolecular Collagen Crosslinks and Advanced GLYCATION End …
    673. The stable products of the non-enzymatic GLYCATION of pig crystallins: new findings related to the pathogenesis of diabetic cataracts.
    674. Isotope effects in the non enzymic GLYCATION of hemoglobin catalyzed by DPG
    675. GLYCATION of hair protein in the assessment of long-term control of blood glucose
    676. The effect of non-enzymatic GLYCATION on mechanical properties of articular cartilage
    677. Differences in nonenzymatic GLYCATION of histones.
    678. [48] GLYCATION of copper/zinc superoxide dismutase and its inactivation: Identification of glycated sites
    679. Synthesis of novel imidazolidinones from hexose–peptide adducts: model studies of the Maillard reaction with possible significance in protein GLYCATION
    680. Investigations on protein nonenzymatic GLYCATION by a new and effective mass spectrometric method
    681. GLYCATION precedes lens crystallin aggregation
    682. Diabetic erythrocytes bearing advanced GLYCATION end products induce vascular dysfunctions
    683. Mass Spectrum in the Study of Advanced GLYCATION End Products
    684. Pancreatic bile-salt-dependent lipase activity in serum of diabetic patients: is there a relationship with GLYCATION?
    685. The advanced GLYCATION endproduct, pentosidine, in the carpal ligament in patients with carpal tunnel syndrome undergoing hemodialysis: comparison with idiopathic …
    686. AL0671, a new potassium channel opener, inhibits nonenzymatic GLYCATION of protein and LDL oxidation.
    687. Enhanced binding of advanced GLYCATION endproducts (age) by apo e4 isotype linkt mechanisms of plaque deposition in alzheimer’s disease
    688. Identification of N2-(1-carboxymethyl) guanine (CMG) as a guanine advanced GLYCATION end product
    689. The assessment of protein GLYCATION in human atherosclerotic plaques by affinity chromatography
    690. The effects of 5% and 25% galactose diets on lens polyols, glutathione and protein GLYCATION in male and female pigs
    691. GLYCATION of blood proteins during pregnancy and lactation in the rat.
    692. Non-enzymic GLYCATION of collagen inhibits binding of oxidized low-density lipoprotein
    693. Influence of factors affecting GLYCATION on defects of dietary copper deficiency
    694. Analysis of furosine as an indicator of lysine residue GLYCATION in milk protein by HPLC
    695. The role of GLYCATION and autoxidation on crystallin aggregation
    696. GLYCATION of human serum albumin in long-term incubation with low and high concentrations of glucose
    697. Massive GLYCATION of protein HC, a low molecular weight lipocalin, in non-diabetic individuals
    698. Alterations in biological activities induced by GLYCATION of leucine-enkephalin with different monosaccharide moieties
    699. Accumulation of GLYCATION products in α‐H pig lens crystallin and its bearing to diabetic cataract genesis
    700. Quantification of GLYCATION-Induced Browning in Lens Crystalline
    701. The effects of silymarin on the inhibition of nonenzymatic GLYCATION and oxidation in aorta of streptozocin-induced diabetic rats
    702. The 32nd Annual Meeting off the European Association for the Study off Diabetes: Neuropathy, health care, and GLYCATION
    703. GLYCATION of Copper, Zine-superoxide Dismutase and Its Effect on the Thiol-Metal Catalyzed Oxidation Mediated DNA Damage
    704. … of the Maillard Reaction by Organic Germanium Compounds. Molecular Mechanism on the Prevention and Reversible Solubilization of Advanced GLYCATION …
    705. Effects of parathyroid hormone and 1, 25 (OH2) D3 on protein GLYCATION in moderate uraemia
    706. Release of fructose and hexose phosphates from perivascular cells induced by low density lipoprotein and acceleration of protein GLYCATION in vitro
    707. Increased GLYCATION of human erythrocyte Cu, Znsuperoxide dismutase in diabetic patients with cataracts and retinopathy
    708. Effects of nonenzymatic GLYCATION on molecular interactions of basement membrane molecules
    709. The GLYCATION of bovine lens β L-, β S-and γ-crystallins demonstrated by frozen-sectioning and isoelectric focusing
    710. Higher GLYCATION of βL-and βS-Crystallins in the Anterior Lens Cortex and Maximum GLYCATION of γ-Crystallins in the Bovine Lens Nucleus, Demonstrated by Frozen …
    711. Characterization of the GLYCATION of human insulin by reversed-phase HPLC
    712. Protein GLYCATION and diabetic vascular disease
    713. GLYCATION of lysozyme in a restricted water environment.
    714. Effect of a low protein diet on the relationship of nonenzymatic GLYCATION to altered renal structure and function in diabetes mellitus
    715. 2-D electrophoresis distribution of stable 14C-GLYCATION products from pig lens crystallins in relation to diabetic cataract formation
    716. The effects of silymarin on the inhibition of nonenzymatic GLYCATION and oxidation in aorta of streptozocin-induced diabetic rats
    717. Effect of aminoguanidine on the GLYCATION.
    718. Failure of glucose-binding lectins Con A and Lentil Lectin to identify GLYCATION of haemoglobin
    719. The pro-oxidant activity of aminoguanidine and protein GLYCATION
    720. 23 GLYCATION and Diabetic Complications
    721. Inhibitory effect of pycnogenol on generation of advanced GLYCATION end products in vitro
    722. Effect of sialic acid on GLYCATION-induced fluorescence of albumin
    723. Expression of advanced GLYCATION end products receptors on human joint synovial cells
    724. Diabetic Atherosclerosis and GLYCATION of LDL (Low Density Lipoprotein)
    725. AMINOPHOSPHOLIPID GLYCATION CAUSES LIPID BILAYER STRUCTURE ALTERATIONS AND INHIBITION OF MEMBRANE-BOUND
    726. … changes in pancreatic islets obtained from obese Zucker rats (fa/fa) on a diabetogenic diet. No evidence for non-enzymatic protein GLYCATION in endocrine cells
    727. Alzheimers disease synergistic effects of glucose deficit, oxidative stress and advanced GLYCATION endproducts
    728. Relation between dialysis-related amyloidosis and advanced GLYCATION end products (AGEs)
    729. Interaction of glycyl-phenylalanine with carbohydrates as a model of N-terminal GLYCATION of proteins
    730. The detection of an early advanced GLYCATION product which co-elutes with the Amadori product on aminophenylboronate affinity chromatography.
    731. GLYCATION and inactivation of rat aldehyde reductase, a major 3-deoxyglucosone reducing enzyme
    732. Influence of aspartic acid and glutamic acid on non-enzymatic GLYCATION of lens proteins in vitro
    733. Advanced GLYCATION end products-induced TNF-? and IL-6 production by peripheral lymphocytes of diabetic patients
    734. Nonenzymatic GLYCATION of human fibrinogen and myelin basic protein
    735. The effect of phenobarbital on the nonenzymatic GLYCATION of hemoglobin.
    736. Alterations of retinal microvascular cell glycoproteins by advanced GLYCATION end products
    737. The effect of non-enzymatic GLYCATION on recombinant human aldose reductase
    738. Establishment of a quantitative RT-pCR for detection of vascular cell adhesion molecule-1 transcripts in endothelial cells after stimulation with advanced GLYCATION …
    739. GLYCATION of human serum albumin by dl-glyceraldehyde: a fluorescence quenching study
    740. Covalent modifications of eye lens proteins by oxidation and GLYCATION
    741. Diabetic control: Studies of protein GLYCATION, microangiopathy and diabetic pregnancy.
    742. International diabetes federation meeting, 1997: nephropathy, retinopathy, and GLYCATION
    743. Non-enzymatic GLYCATION of human serum albumin: influence on thebinding kinetics of the benzodiazepine binding sites
    744. Neuroelectrophysiological abnormalities are related to metabolic and advanced non-enzymatic GLYCATION changes in prospectively evaluated diabetic Sprague …
    745. Blocking effect of quercetin on the nonenzymatic GLYCATION of aortic collagen [J]
    746. Dietary restriction diminishes early GLYCATION adducts on murine hepatic cytosolic proteins
    747. Depolymerization of hyaluronan induced by GLYCATION reaction: possible role in vitreous liquefaction
    748. The effects of Silymarin on the inhibition of nonenzymatic GLYCATION and oxidation in kidneys of streptozocin-induced diabetic rats [J]
    749. Monocyte/macrophage receptors for proteins modified by advanced GLYCATION end products: role in normal tissue remodeling and in pathology
    750. Flavonoids and flavonoid metabolites inhibit monosaccharide-induced protein damage of the advanced GLYCATION end product (AGE) type
    751. PREVENTION OF THE MAILLARD REACTION AND REVERSIBLE DESTRUCTION OF ADVANCED GLYCATION END PRODUCTS (AGE) BY NOVEL ORGANIC …
    752. GLYCATION and the Development of Arteriosclerosis
    753. Alteration in coagulation and fibrinolytic activities of glycated fibrinogen from diabetic patients and inhibitory effect of drugs on GLYCATION of fibrinogen
    754. Factors affecting the GLYCATION of proteins
    755. The Effect of Vitamin E on Protein GLYCATION in NIDDM Patients
    756. Method for analyzing the GLYCATION of hemoglobin
    757. GLYCATION and the Development of Diabetic Retinopathy
    758. Cellular Receptors for Advanced GLYCATION Endproducts
    759. Pharmacologic importance of GLYCATION of plasma proteins
    760. Faba bean albumins GLYCATION
    761. In vitro GLYCATION of dried serum
    762. GLYCATION of liver alcohol dehydrogenase.
    763. GLYCATION Inhibitors and the Prevention of Diabetic Complications
    764. Role of Fructose in GLYCATION
    765. GLYCATION of proteins and development of vascular disease in diabetes mellitus
    766. GLYCATION: A vascular enemy of many faces
    767. Nonenzymic GLYCATION of Hemoglobin: Structural Determinants of Site Selectivity
    768. GLYCATION of H1-histone.
    769. The possible role of GLYCATION in the pathogenesis of atherosclerosis
    770. IN VITRO GLYCATION OF HEMOGLOBIN (HB): CHOOSING THE APPROPRIATE MODEL
    771. Enzyme-linked immunosorbent assay development for advanced GLYCATION end products and brochocin-C.
    772. Advanced GLYCATION end-products induce global endothelial activation
    773. GLYCATION of apolipoprotein E in vitro and its binding to heparin
    774. Evidence for Nonenzymic GLYCATION of Antithrombin III in Diabetic Patients
    775. GLYCATION of basement membranes: Location of advanced GLYCATION end products within type IV collagen and their effect on degradation by matrix proteases.
    776. Influence of Albumin GLYCATION on the Protein Binding of Drugs
    777. Bendazac decreases in vitro GLYCATION of human lens crystallins
    778. Effects of vitamin E on secretion of inflammatory mediators of human monocytes by advanced GLYCATION end products
    779. Impaired glucose tolerance, angiopathy and advanced GLYCATION end products
    780. ADVANCED GLYCATION END PRODUCTS MODIFIED PROTEIN UP-REGULATES EXPRESSION OF ADHESION MOLECULES ON HUMAN ENDOTHELIAL CELLS
    781. GLYCATION and the Maillard Reaction in vitro: Implications for Diabetes Mellitus
    782. THE RELEVANCE OF PROTEIN GLYCOSYLATION TO DIABETES AND AGEING (ADVANCED GLYCATION ENDPRODUCTS, GLYCAEMIC CONTROL).
    783. Impaired Immunoglobulin G Fc Fragment Function in Diabetics is Caused by a Mechanism Different from GLYCATION
    784. The influence of aging and GLYCATION on protein-thiol mixed disulfides in the eye lens.
    785. GLYCATION-dependent, Reactive Oxygen Species-mediated Suppression of the Insulin Gene Promoter Activity in HIT Cells
    786. The role of GLYCATION and free radicals in hyperglycemia-induced malformations
    787. Participation of advanced GLYCATION end products in actinic elastosis.
    788. Advanced GLYCATION end products cross-links and diabetic-induced endothelium dysfunction
    789. Advanced GLYCATION Dependent Formation of Modified o-Crystallin and High Molecular Weight Aggregates
    790. Advanced GLYCATION End Products and Loss of Pericytes in Early Diabetic Retinopathy
    791. Advanced GLYCATION endproducts stimulate interleukin-6 production by human bone-derived cells
    792. In vivo GLYCATION of aldehyde reductase, a major 3-deoxyglucosone reducing enzyme: identification of GLYCATION sites
    793. Effect of advanced GLYCATION end-products on the generation of macrophage-mediated oxidized low-density lipoprotein
    794. Structural and functional consequences of non-enzymatic